Stone House Investment Management’s Myriad Genetics MYGN Stock Holding History

Stone House Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.71K	Hold	1,000	–	–	﹤0.01%	533
2026 Q1	$4.5K	Hold	1,000	–	–	﹤0.01%	471
2025 Q4	$6.15K	Hold	1,000	–	–	﹤0.01%	392
2025 Q3	$7.23K	Hold	1,000	–	–	﹤0.01%	323
2025 Q2	$5.31K	Hold	1,000	–	–	﹤0.01%	318
2025 Q1	$8.87K	Buy	+1,000	New	+$12K	﹤0.01%	263
2024 Q4	–	Sell	-1,000	Closed	-$27.4K	–	245
2024 Q3	$27.4K	Hold	1,000	–	–	0.01%	158
2024 Q2	$24.5K	Hold	1,000	–	–	0.01%	170
2024 Q1	$21.3K	Hold	1,000	–	–	0.01%	184
2023 Q4	$19.1K	Hold	1,000	–	–	0.01%	124
2023 Q3	$16K	Hold	1,000	–	–	0.01%	130
2023 Q2	$23.2K	Hold	1,000	–	–	0.01%	108
2023 Q1	$23.2K	Buy	+1,000	New	+$20.3K	0.01%	119
2019 Q2	–	Sell	-154	Closed	-$5K	–	143
2019 Q1	$5K	Buy	+154	New	+$4.69K	﹤0.01%	183

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stone House Investment Management's MYGN Position: Q2 2026 in Review

Stone House Investment Management held its Myriad Genetics (MYGN) position steady in Q2 2026 at 1,000 shares worth $5.71K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

Stone House Investment Management first reported a position in MYGN in Q1 2019 and has held it in 14 quarters since. The position peaked at $27.4K in Q3 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Stone House Investment Management held 1,000 shares of Myriad Genetics worth $5.71K as of Q2 2026.
Stone House Investment Management left its Myriad Genetics share count unchanged in Q2 2026.
Myriad Genetics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #533 holding.
Stone House Investment Management first reported a position in Myriad Genetics in Q1 2019 and has held it in 14 quarters since.
Stone House Investment Management's Myriad Genetics position peaked at $27.4K in Q3 2024.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.